Introduction
============

Serotonin (5-HT) is a biogenic amine acting as a neurotransmitter and neuromodulator. The distribution of serotonin-containing neurons in the CNS have been studied in different species and have been found to be localized exclusively in the brainstem ([@B67]; [@B146]; [@B69]). The majority of the serotonergic cell bodies reside in the dorsal and median raphe nuclei but send axons almost to the entire brain, including cortical, limbic, midbrain, and hindbrain regions ([@B29]). As expected from the wide projection pattern of the 5-HT neurons, serotonin modulates variable physiological functions, such as sleep, arousal, feeding, temperature regulation, pain, emotions, and cognition ([@B23]; [@B10]; [@B112]; [@B14]; [@B4]).

The pleiotropic behavioral effects of 5-HT are mediated by a family of at least 14 5-HTR subtypes ([@B64]). These 5-HTR subtypes are distributed in a brain- and cell-specific manner and regulate distinct physiological processes, through different and sometimes opposing signaling pathways ([@B66]; [@B65]).

The 5-HT~1A~R is one of the best-studied 5-HTR subtypes due to its implication in anxiety-like behaviors ([@B56]; [@B114]; [@B152]), in depression ([@B88]) as well as in cognitive processes that are impaired in several psychiatric disorders (review by [@B112]; [@B99]). Its potential role as a drug target has been also investigated ([@B154]; [@B37]; [@B18]). The most common antidepressants, the SSRIs, act by targeting the 5-HT~1A~R ([@B57]; [@B4]), supporting the key role of the 5-HT~1A~R in the pathophysiology of mood disorders.

The 5-HT~7~Rs are implicated in depression and anxiety, and evidence has been provided for their role in learning and memory (reviewed by [@B82]). Interestingly, the 5-HT~7~R and 5-HT~1A~R exert opposing roles in the modulation of fear learning ([@B41], [@B40]), pointing at the importance of both 5-HTR subtypes and their signaling interaction in the regulation of emotional learning.

After a brief introduction about the characteristics of 5-HT~1A~ and 5-HT~7~R (distribution, signaling, and ligands), this review will focus on the role of 5-HT~1A~R, 5-HT~7~R as well as its interplay in emotional learning processes. The interaction between the 5-HT~1A~R and 5-HT~7~R signaling will be discussed and results of studies using different available 5-HT~1A~R and 5-HT~7~R ligands on fear learning tasks are summarized. A considerable extent of this review will also be dedicated to describe the region-specific effects of 5-HT~1A~R and 5-HT~7~R, via local rather than systemic administration. Overall, the aim of this review is to draw general conclusions about the role of both 5-HT~1A~R and 5-HT~7~R in fear learning, which may contribute to our better understanding of the mechanisms underlying dysregulated learning and memory in affective disorders. The focus here is on fear learning because this one-trial learning task allows for exact timing of pharmacological manipulations to discriminate between different memory phases.

Characteristics of the 5-HT~1A~ and 5-HT~7~ Receptors
=====================================================

All the 5-HTR subtypes belong to the G protein-coupled receptor superfamily, with the exception of the 5-HT~3~R as ionotropic receptor ([@B65]). The metabotropic 5-HTR subtypes consist of seven transmembrane domains and are classified into four groups based on the type of G proteins to which they are coupled. The 5-HT~1~Rs (5-HT~1A~R, 5-HT~1B~R, 5-HT~1D~R, 5-HT~1E~R, 5-HT~1F~R) couple to Gα~i~/Gα~o~ proteins, whereas the 5-HT~2~Rs (5-HT~2A~R, 5-HT~2B~R, 5-HT~2C~) couple to Gα~q~ proteins, and the 5-HT~4~R, 5-HT~6~R, and 5-HT~7~R couple to Gα~s~ proteins. For the 5-HT~5~Rs (5-HT~5A~R and 5-HT~5B~R) G-protein coupling is not established yet ([@B19]).

5-HT~1A~ Receptor Localization
------------------------------

5-HT~1A~R was the first 5-HTR subtype to be cloned and is characterized by its high affinity for 5-HT ([@B110]). 5-HT~1A~Rs are widely distributed throughout the CNS and are present in both pre- and postsynaptic sites. Presynaptically, 5-HT~1A~Rs are exclusively located on the cell bodies and dendrites of 5-HT neurons in the dorsal and median raphe nuclei ([@B127]) and function as 5-HT~1A~ autoreceptors which tightly regulate 5-HT neuronal activity.

Postsynaptically, the highest level of 5-HT~1A~R is found in the limbic system based on receptor autoradiography and mRNA expression. Both techniques showed the distribution of the 5-HT~1A~R in the lateral septum, cingulate and entorhinal cortices, with particularly high expression in the hippocampus (reviewed by [@B55]). At the cellular level, the postsynaptic 5-HT~1A~R is expressed in cortical pyramidal neurons as well as pyramidal, GABAergic and granular cells of the hippocampus ([@B55]). At least in the hippocampal formation, the 5-HT~1A~R is located on somata and dendrites of pyramidal and granular neurons, as well as on the dendritic spines of pyramidal neurons ([@B127]). Moreover, 5-HT~1A~R immunoreactivity has been demonstrated in different subgroups of neurons in the septal complex with GABAergic septohippocampal parvalbumin-containing projection neurons, GABAergic calbindin D-28-containing neurons as well as cholinergic septohippocampal neurons ([@B89]). This indicates that systemic administration of 5-HT~1A~R ligands can modify hippocampal function through effects on septohippocampal neurons that are responsible for the theta rhythm which plays an important role in memory functions ([@B39]).

5-HT~1A~ Receptor Signaling
---------------------------

Activation of 5-HT~1A~R leads to neuronal hyperpolarization, an effect mediated by pertussis-toxin-sensitive Gα~i/o~ proteins. Gα~i/o~ proteins are negatively coupled with the signaling pathway of adenylyl cyclase and thereby decrease the cAMP formation ([@B34]; [@B157]). Despite their high density in the dorsal raphe nucleus, 5-HT~1A~ autoreceptors do not seem to inhibit AC, but mediate neuronal inhibition through different signaling pathways ([@B31]). Both post- and presynaptic 5-HT~1A~Rs inhibit neuronal firing via the activation of G protein-coupled inwardly rectifying potassium channels as well as the inhibition of Ca^2+^ channels ([@B139]; [@B19]). A multitude of other signaling pathways and effectors has been also linked to the activation of the 5-HT~1A~R (reviewed by [@B125]; [@B19]).

5-HT~7~R Localization
---------------------

The 5-HT~7~R was the last 5-HTR subtype to be cloned by using a targeted screening analysis of mammalian cDNA libraries and probes from already known receptors ([@B9]; [@B87]; [@B130]). Although 5-HT~7~Rs demonstrate a high interspecies homology (\>90%; [@B150]), they share a low homology with the other 5-HTR subtypes (\<50%; [@B9]). Northern blot analysis and *in situ* hybridization studies demonstrate high expression of 5-HT~7~R in the CNS and particularly in the hypothalamus (suprachiasmatic nucleus), thalamus, hippocampus, and cerebral cortex ([@B9]; [@B87]; [@B130]). Like 5-HT~1A~R, the 5-HT~7~R is also localized in the raphe nuclei in both rodent and human brain, which has raised questions about its role in the regulation of 5-HT levels ([@B93]). At the neuronal level, 5-HT~7~R is expressed in hippocampal CA pyramidal neurons with a higher density in CA3 than in CA1 ([@B20]) and a differential expression, with selective localization on the cell bodies in CA1 pyramidal neurons ([@B17]). Little is known, however, about the expression patterns of 5-HT~7~R in cortical neurons, where it is suggested that 5-HT~7~R may have a role during the developing stages of cortical circuits ([@B13]; [@B28]).

5-HT~7~ Receptor Signaling
--------------------------

5-HT~7~R activation activates adenylyl cyclase signaling and consequently the conversion of ATP to cAMP through coupling to Gα~s~ ([@B9]; [@B87]; [@B130]). Although cAMP activation is commonly mediated by the PKA, it has been demonstrated that Epac, a member of the cAMP-regulated guanine nucleotide exchange family, has a crucial role in PKA-independent signaling ([@B85]). For instance, 5-HT~7~Rs activate the MAPK/ERK signaling pathway ([@B42]; [@B111]) via the stimulation of the Epac factor ([@B85]). Binding of cAMP to Epac leads to the activation of several other signaling pathways (reviewed by [@B61]).

Functional Roles of 5-HT~1A~R and 5-HT~7~ Receptors
===================================================

The expression of 5-HT~1A~R and 5-HT~7~R in the limbic system ([@B55]; [@B16]) support a role in the modulation of functions like mood, memory processing as well as emotional association with memory. The 5-HT~1A~R has been proposed to modulate anxiety based on studies with 5-HT~1A~R knockout mice ([@B56]; [@B114]; [@B152]) and the response to antidepressant drugs ([@B18]; [@B4]). Several partial 5-HT~1A~R agonists, e.g., buspirone, have been used to treat anxiety and depression ([@B154]; [@B37]), whereas co-administration of pindolol (β-adrenergic and 5-HT~1A~R antagonist) with SSRIs enhances their therapeutic efficacy and shortens their onset of action (reviewed by [@B5]). A considerable body of literature demonstrates the 5-HT~1A~R involvement in various hippocampus-dependent learning and memory tasks (reviewed by [@B112]).

In contrast, the available data on the function of 5-HT~7~R is relatively limited, mainly due to the lack of selective agonists specific for this 5-HTR subtype ([@B104]; [@B110]; [@B82]). The physiological role of 5-HT~7~R has been closely linked with the regulation of sleep, circadian rhythm, pain and also mood (reviewed by [@B82]). Accumulating data implicates the 5-HT~7~R in the action of antidepressant drugs, whereas the results from anxiety studies are contradictory ([@B82]). Interestingly, studies using 5-HT~7~R knockout mice revealed the crucial role of this receptor in hippocampus-dependent memory ([@B128]; [@B132]).

5-HT~1A~ and 5-HT~7~ Receptor Ligands
=====================================

General Receptor Ligand Principles
----------------------------------

Agents that act as receptor ligands may be agonists or antagonists. Agonists initiate physiological changes by activating downstream signaling pathways, whereas antagonists bind to receptors without producing any effect ([@B123]). Ligands can be divided in three categories based on their function:

1.  Full agonists produce a maximal response equivalent to the endogenous agonist (here 5-HT). These agonists have high efficacy (i.e., the ability to initiate changes which leads to effects) for the binding receptor.

2.  Partial agonists are not capable of producing the maximal functional response even when they occupy the entire receptor population. These agonists present intermediate efficacy. Respectively, we could refer to partial antagonists that bind to the active site (competitive antagonism) but do not completely abolish the receptor-mediated effects.

3.  Mixed profile ligands that (appear to) act both as agonists and as antagonist in distinct receptor populations. More likely, they have different agonist profiles at different receptor sites (e.g., pre-versus postsynaptic 5-HT~1A~R) and therefore appear to exert antagonist function in the presence of a full agonist, while acting as weak (partial) agonist thereby lowering the efficacy of the full agonist.

The function of any ligand used to study the role of 5-HT~1A~R and 5-HT~7~R is essential for the correct interpretation of the behavioral outcome. It is also important to mention that the intrinsic efficacy of a ligand is equally depended on the characteristics of response system; in our case the different brain populations of 5-HT~1A~R and 5-HT~7~R and their downstream signaling pathways. Agonists acting on the same receptor can produce different effects depending on their physicochemical properties, brain distribution, full or partial agonism as well as the number of coupled receptors in a brain area. The specificity of the compounds used is another very important characteristic that should be always taken into consideration and is referred to the ligand's specific binding to the targeted receptor. Ligands with low specificity cannot be used to clarify the functional role of 5-HT~1A~R and 5-HT~7~R, since the produced effects can be also mediated via the binding to other proteins than the receptor of interest.

The physicochemical properties of compounds play an essential role for the drug uptake and diffusion with lipophilicity, solubility and molecular mass being among the most important properties ([@B156]). The lipophilic nature of ligands is particularly important when they are administered locally. Increasing lipophilicity leads to enhanced blood--brain barrier diffusion, prevents the drug restriction in the area of interest and consequently produces wider effects, despite local application. This is evident from dorsohippocampal infusion of the blood--brain barrier penetrating drug 8-OH-DPAT, a full 5-HT~1A~R agonist, which impairs tone-dependent memory ([@B143]), whereas this does not occur when the NMDAR antagonist APV ([@B144]) and the GABA~A~R agonist muscimol are locally applied ([@B103]). The latter study is one of the few demonstrating the selective drug action in the dorsal hippocampus based on fluorescently labeled muscimol as bodipy conjugate. Besides the solubility of compounds and the applied dose, it is thus of high importance to consider other physico-chemical properties, such as half-life *in vivo*, to avoid misleading conclusions due to their wider spread (e.g., diffusion or potential active transport) in brain outside the target sites. The molecular weight of compounds can also provide valuable information about the diffusion capacity.

5-HT~1A~ Receptor Agonists
--------------------------

The prototypic 5-HT~1A~R agonist 8-OH-DPAT was the first full agonist developed ([@B6]; [@B47]) and is still the most widely used to study the functional role of 5-HT~1A~R in behavioral manipulations ([@B10]). Despite its high selectivity for the 5-HT~1A~R, 8-OH-DPAT also acts as a 5-HT~7~R agonist ([@B17]; [@B41]) and observed effects can be the result of an interplay between the two receptor subtypes (see below).

Additionally, several full and partial agonists have been synthesized (see **Table [1](#T1){ref-type="table"}**), but only a few of them have been used in fear learning studies, such as the buspirone and tandospirone. Buspirone belongs to the arylpiperazine (partial) agonists ([@B60]) and acts also as antagonist with high specificity for the dopamine D~2~ receptor ([@B159]). Tandospirone (SM-3997) is a 5-HT~1A~R partial agonist and was initially studied for its anxiolytic properties in rats and mice ([@B136]). Similar to buspirone, tandospirone also exhibits dopamine antagonist action with a potency that is considerably lower than the one for the 5-HT~1A~R ([@B136]). An overview of currently available 5-HT~1A~R agonists is provided in **Table [1](#T1){ref-type="table"}**.

###### 

Selected overview on available 5-HT~1A~ receptor agonists and ligands with mixed profile (reported function as presynaptic agonist and postsynaptic antagonist).

  Function        Compound                  Receptor Specificity                                                             MW      Solvent   BBB penetr.   Behavior   Reference
  --------------- ------------------------- -------------------------------------------------------------------------------- ------- --------- ------------- ---------- ----------------------
  Full/partial    Alnespirone (S-20499)     5-HT~1A~ \>\> D~2~ \>\> 5-HT~1B,2~ \>\> α,β \>\> D~1~ \>\> H~1~ (pre-synaptic)   479     W         n.a.          A          [@B50]
  Partial         Buspirone                 5-HT~1A~ = D~2~ \>\> α~1~,α~2~                                                   385.5   W         n.a.          A, L       [@B60], [@B121]
  Full            F-13640                   5-HT~1A~ \>\> n.a.                                                               393.1   w         Yes           N          [@B38], [@B58]; GtP
  Partial         F-13714                   5-HT ~1A~ \>\> 5-HT [~1B-F,2-7~]{.smallcaps}                                     n.a.    w         n.a.          PPI        [@B7]
  Full            F-15599                   5-HT~1A~ (post-synaptic) \>\> 5-HT~1B-F,2-7~                                     394.1   n.a.      Yes           FST        [@B95], [@B109]; GtP
  Full            Flesinoxan                5-HT~1A~ \>\> α~1~ (antagonist) \>\> D~2~                                        415.5   W         Yes           A          [@B1], [@B52]
  Partial         Ipsapirone (TVX Q 7821)   5-HT~1A~ \>\> α~1~ (antagonist)                                                  401.5   w         Yes           A          [@B153]
  Partial/full    LY-228729                 5-HT~1A~ \>\> 5-HT~1B~                                                           n.a.    w         n.a.          L, FST     [@B145]
  n.a.            NDO-008                   5-HT~1A~ \>\> n.a.                                                               n.a.    w         n.a.          L          [@B102]
  Full            8-OH-DPAT                 5-HT ~1A~ \>\> 5-HT~7~ \>\> 5-HT~4~ \>\> D~2~                                    328.3   w         Yes           A, L       [@B6], [@B52]
  Full/Partial    Osemozotan (MKC-242)      5-HT~1A~ \>\> α~1~                                                               379.8   w         n.a.          A          [@B94], [@B131]
  Partial         PRX-00023                 5-HT ~1A~ \>\> 5-HT ~1B~\>α~1~\>α~2~                                             n.a.    w         n.a.          A          [@B12]
  Full            Repinotan (BAY x 3702)    5-HT ~1A~ \>\> 5-HT~7~ \>\> α~1~\>α~2~\>5-HT~4~                                  400.5   HC1       Yes           L          [@B35], [@B135]
  Partial         Tandospirone (SM-3997)    5-HT~1A~ \>\> D~2~                                                               383.5   w         n.a.          A, L       [@B136]
                                                                                                                                                                        
  Mixed profile   S-15535                   n.a.                                                                             432.5   w         Yes           A, L       [@B100], [@B26]
  Mixed profile   MDL-73005                                                                                                  n.a.    w         n.a.          L          [@B54], [@B15]

A, anxiety; BBB, blood--brain barrier; D: FST; forced swim test; GtP, guide to pharmacology, see

http://guidetopharmacology.org/

; HCl, soluble in acidified aqueous solution; L, learning and memory tests; N, nociception; n.a., not available; penetr., penetrance; PPI, pre-pulse inhibition; W, soluble in water and/or saline.

5-HT~1A~ Receptor Antagonists
-----------------------------

WAY-100635 and NAD-299 are the most commonly used selective antagonists in the study of the 5-HT~1A~R. Both ligands have high potencies and penetrate easily into the brain ([@B45]; [@B71]; [@B141]). However, NAD-299 was found to have higher selectivity for the 5-HT~1A~R than WAY-100635 ([@B45]; [@B71]).

The last years novel compounds have been used to assess the role of 5-HT~1A~R in emotional learning, such as the potent and selective 5-HT~1A~R antagonists SRA-333 (lecozotan; [@B138]), MC18 fumarate and VP08/34 fumarate ([@B137]; [@B119]).

The agents that were initially used as 5-HT~1A~R antagonist were 2-methoxyphenylpiperazine derivatives with structural similarity to buspirone, such as BMY-7378 and NAN-190 ([@B49]). However, these ligands were characterized as partial 5-HT~1A~R antagonist with antagonist properties only at the postsynaptic HT~1A~R and lower affinity for the α-adrenergic receptors ([@B49]).

Finally, S-15535 is reported to act as a postsynaptic 5-HT~1A~R antagonist while also behaving as an agonist on presynaptic 5-HT~1A~ autoreceptors, and therefore, it is characterized as a mixed profile ligand ([@B100]; [@B26]). However, a more recent study indicates predominantly weaker agonist activity of S-15535 at postsynaptic 5-HT~1A~Rs ([@B161]). An overview of currently available 5-HT~1A~R antagonists is provided in **Table [2](#T2){ref-type="table"}**.

###### 

Selected overview on available 5-HT~1A~ receptor antagonists.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Function   Compound              Receptor specificity                                                                    MW            Solvent   BBB penetr.   Behavior   Reference
  ---------- --------------------- --------------------------------------------------------------------------------------- ------------- --------- ------------- ---------- -----------------------------------------------------
  Partial    BMY-7378              5-HT~1A~ \>\> α~1~ \>\> α*~2~* (partial agonist function) \>\> 5-HT~7~ \>\> 5-HT ~1D~   385.9         W         \+            A, L       [@B49], [@B48]

  Partial    LY-426965             HT~1A~ \>\> 5-HT~1B~ (partial agonist function)                                         471.1         W         n.a.          A          [@B124]; <http://sis.nlm.nih.gov/>

             MC18 fumarate         5-HT~1A~ \>\> n.a                                                                       515.7         W         n.a.          L          [@B119]

             MP3022\               5-HT~1A~ \>\> α~1~ \>\> 5-HT~2A~, α~2~, β, D~1~ and D~2~\                               351.5 354.9   n.a.\     n.a.\         n.a.\      [@B44]\
             \                     5-HT~1A~ \>\> α~1~,α~2~, β                                                                            \         \             \          [@B71], [@B91]; <http://chem.sis.nlm.nih.gov/>
             NAD-299 (Robalzotan                                                                                                         W         +             A, L       

  Partial    NAN-190               HT~1A~ \>\> α~1~ (partial agonist function reported) \>\> 5-HT~R~, D                    393.5         W         n.a.          A, L       [@B122], [@B49]

             p-MPPI                5-HT~1A~ \>\> α~1~                                                                      542.4         W         \+            A          [@B78], [@B2]; <http://pubchem.ncbi.nlm.nih.gov/>

             p-MPPF                5-HT~1A~ \>\> α~1~                                                                      507.4         n.a.      \+            n.a.       [@B79], [@B115]; <http://pubchem.ncbi.nlm.nih.gov/>

             SB-649915             n.a., combined function as 5-HT~1A/B~ autoreceptor antagonist and SSRI                  n.a.          MC        n.a.          A          [@B140]

             Spiperone             5-HT~1A~ \>\> 5-HT~2A/c~ \>\> D~2~ antagonist and α~lb~ antagonist                      n.a.          MC        n.a.          A          [@B140]

             SRA-333 (Lecozotan)   5-HT~1A~ \>\> α~1~ \>\> D~2~ \>\> D~3~ \>\> D~4~ (α and D agonist)                      n.a.          W         n.a.          A, L       [@B134]

             (S)-UH-301            5-HT~1A~ \>\> D~2~, D~3~ (agonist)                                                      301.8         W         Yes           A, L       [@B107], [@B70]

             VP-08/34 fumarate     5-HT~1A~ \>\> n.a                                                                       513.6         W         Yes           L          [@B119]

             WAY-100635            5-HT~1A~ \>\> α~1~ \>\> D~2~ \>\> D~3~ \>\> D~4~                                        538.6         W         Yes           A, L       [@B45], [@B117]

             WAY-405               5-HT~1A~ \>\> α                                                                         n.a.          MC        Yes           A, L       [@B101], [@B155]

             WAY-101405            5-HT~1A~ \>\> n.a                                                                       n.a.          W         Yes           L          [@B59]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A, anxiety; BBB, blood--brain barrier; D: FST, forced swim test; L, learning and memory tests; MC, methylcellulose; n.a., not available; penetr., penetrance; PPI, pre-pulse inhibition; S\*, 2-hydroxypropyl-β-cyclodextrin; W, soluble in water and/or saline.

5-HT~7~ Receptor Agonists
-------------------------

The lack of selective and potent 5-HT~7~R agonists ([@B104]; [@B81]; [@B82]) is one of the major limitations to study the role of 5-HT~7~R in learning and memory. Currently, only a few selective 5-HT~7~R agonists exist and even less has been used in learning and memory studies. AS-19 and LP-44 are highly selective but low efficacy (partial) HT~7~R agonists whose functional role in fear learning was recently assessed ([@B40]). LP-211 is a novel highly selective 5-HT~7~R agonists ([@B83]) but it has so far only been tested in an autoshaping Pavlovian/instrumental learning task ([@B98]). An overview of currently available 5-HT~7~R agonists is provided in **Table [3](#T3){ref-type="table"}**.

###### 

Selected overview on available 5-HT~7~ receptor agonists and antagonists.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Function          Compound        Receptor specificity                                                               MW       Solvent   BBB penetr.   Behavior       Reference
  ----------------- --------------- ---------------------------------------------------------------------------------- -------- --------- ------------- -------------- ---------------------------------------------------------------------
  **Agonists**                                                                                                                                                         

  Partial           AS-19           5-HT~7~ \>\> n.a.                                                                  283.41   PG        n.a.          L, N           [@B24], [@B40]

  Full              E-55888         n.a.                                                                               257.4    W         n.a.          N              [@B24];\
                                                                                                                                                                       <http://pubchem.ncbi.nlm.nih.gov/>

  n.a.              LP-211          5-HT~7~ \>\> D~2~ \> 5-HT~1A~                                                      466.6    DMSO      Yes           L              [@B83], [@B98]; <http://pubchem.ncbi.nlm.nih.gov/>

  Partial           LP-44           5-HT~7~ \>\> 5-HT~1A~ (agonist function) \>\> 5-HT~2A~                             488.1    PG        Yes           L, REM Sleep   [@B106], [@B40]; <http://pubchem.ncbi.nlm.nih.gov/>

  Partial           MSD-5a          5-HT~7~ \>\> 5-HT~1A~ \>\> 5-HT~2A~ \>\> D~2~                                      n.a.     W         n.a.          N              [@B149], [@B24]

  **Antagonists**                                                                                                                                                      

                    DR4004          5-HT~7~ \>\> 5-HT~2~ \> D~2~ \> HT~1A~ \> HT~6~ \> HT~4~                           382.5    T80       A, L          n.a.           [@B75];\
                                                                                                                                                                       <http://pubchem.ncbi.nlm.nih.gov/>

                    SB-258719       5-HT~7~ \>\> 5-HT~1D~ \>\> D~2~, D~3~ \>\> 5- \>\> 5-HT~1B~,5-HT~2B~ \>\> HT~1A~   338.5    W         n.a.          N              [@B46], [@B24]; <http://pubchem.ncbi.nlm.nih.gov/>

                    SB-269970^∗^    5-HT~7~ \>\> 5-HT~5A~ \>\> D~2~ \> 5-HT~1B~ \> HT~1D~                              352.5    T80       Yes           A, FST, L      [@B86], [@B147], [@B158], [@B40]; <http://pubchem.ncbi.nlm.nih.gov>

                    SB-656104-A     5-HT~7~ \>\> 5-HT~1D~ \> 5-HT~2A~ \>HT~2B~\>D~2~ \>5-HT~5A~                        n.a      MC        Yes           L, REM Sleep   [@B148], [@B63]

                    SB-258741^∗∗^   5-HT~7~ \>\> 5-HT~1A~ \> D~3~ \> HT~1B~, D~2~ \> 5-HT~1D~                          350.5    W         n.a.          SZ             [@B86], [@B120]; <http://pubchem.ncbi.nlm.nih.gov/>
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A, anxiety; BBB, blood--brain barrier; DMSO, dimethyl sulfoxide; FST, forced swim test; L, learning and memory tests; MC, methylcellulose; n.a., not available; penetr., penetrance; PG, propylene glycol; PPI, pre-pulse inhibition; SZ, schizophrenia assays; T80: Tween 80; W: soluble in water and/or saline; \*behaves as quasi-full inverse agonist (

Mahé et al., 2004

); \*\*behaves as partial inverse agonist (

Mahé et al., 2004

).

5-HT~7~ Receptor Antagonists
----------------------------

SB-258719 is the first selective 5-HT~7~R antagonist described ([@B46]) but has not yet been used to investigate the role of 5-HT~7~R in the modulation of emotional learning. Both SB-656104-A and SB-269970 possess high potency and selectivity for 5-HT~7~R ([@B86]; [@B147], [@B148]). These are the most commonly used 5-HT~7~R antagonists in behavior studies. An overview of currently available 5-HT~7~R antagonists is provided in **Table [3](#T3){ref-type="table"}**.

Behavioral Tasks for the Assessment of Emotional Learning and Memory
====================================================================

The experimental studies on emotional learning and memory in animals are based originally on psychological analysis of conflict behavior involving approach and avoidance of conditioned stimuli. Traditionally, the assays used to investigate animal behavior are based on the association of pleasant (i.e., motivationally related reward like food) or aversive stimuli (i.e., conditions related to negative feelings like pain and danger) to environmental cues involving classical (Pavlovian) or instrumental conditioning ([@B113]).

The FC and the PA tasks are the most commonly used associative learning paradigms based on contextual fear learning. This type of learning is dependent on the operation of neuronal circuits in the limbic system, such as hippocampus and amygdala ([@B25]; [@B80]) as demonstrated by us in mice (e.g., [@B143],[@B144]; [@B8]). Unlike FC, PA also includes instrumental learning. In the step-through PA test, the animal needs to suppress its innate preference for the dark compartment (where it previously received a foot shock) and remain in the bright compartment. In the step-down PA paradigm, however, the retention is examined in the dark compartment, where the animal received the foot shock (unconditioned stimulus) after stepping down from an elevated platform. The PA test procedure can be modified to examine any facilitating effect of the treatment on PA retention ([@B91]). More specific information on the PA task is provided elsewhere ([@B113]). A refined version of this task may provide for better translational aspects to assess pathological fear states such as post-traumatic-like responses based on deliberate choice of mice ([@B53]).

The single-trial learning design of FC and PA, which is sufficient to establish long-term and remote memory, allows the exact timing of the drug treatment in relation to training and retention test. Thereby, unlike multi-session tasks, one-trial tasks provide a unique advantage to study learning mechanisms as well as drug effects (here 5-HT~1A~R and 5-HT~7~R ligands) on the different phases of learning and memory, i.e., the acquisition phase that consists of encoding and early consolidation, consolidation, the recall (retrieval and expression) phase as well as the extinction phase and reconsolidation.

Effects of 5-HT~1A~ Receptor Ligands in Emotional Learning and Memory
=====================================================================

An overview of the behavioral effects of various 5-HT~1A~R ligands is provided in **Table [4](#T4){ref-type="table"}**.

###### 

Overview of the behavioral effects of 5-HT~1A~ receptor agonists, ligands with mixed profile and antagonists in fear learning tasks.

  Compound            Species: Strain   Time of injection   Dose (mg/kg)   Admin. route   Behavior assay and behavioral consequences                                                     Reference
  ------------------- ----------------- ------------------- -------------- -------------- ---------------------------------------------------------------------------------------------- -----------
  **Agonists**                                                                                                                                                                           
  Buspirone           M: Swiss-W.       30 min pretr.       1              s.c.           FC: reduced freezing in 24-h delay                                                             [@B121]
  NDO-008             R: Sprague-D.     15 min pretr.       0.25--1.0      s.c.           PA: impaired PA retention at 24-h test                                                         [@B102]
  8-OH-DPAT           M: C57BL/6J       15 min pretr.       0.05 and 1     s.c.           FC: impaired freezing at 1-h and 24-h test                                                     [@B143]
                                        0 min post-tr.      0.05 and 1     s.c.           FC: no effect                                                                                  [@B143]
                                        15 min pretr.       2 × 2.5 μg     i.h.           FC: impaired freezing at 24-h test                                                             [@B143]
                      M: C57BL/6J       15 min pretr.       0.3            s.c.           PA: impaired PA retention at 24-h test                                                         [@B40]
  Tandospirone        M: Swiss-W.       30 min pretr.       2 and 5        s.c.           FC: reduced freezing at 24-h test                                                              [@B121]
                      M: Swiss-W.       30 min pretr.       2 and 5        s.c.           FC: no effect at 1-h test                                                                      [@B121]
                      M: Swiss-W.       30 min pretest      2 and 5        s.c.           FC: no effect                                                                                  [@B121]
                      M: Swiss W.       30 min pretr.       2.5 and 5      s.c.           PA: DD PA retention impairment                                                                 [@B96]
  **Mixed profile**                                                                                                                                                                      
  MDL-73005           R: Long-E.        15 min pretr.       2              i.p            MWM: no effect alone but prevented the memory impairment induced by scopolamine (0.25 mg/kg)   [@B15]
  S15535              M: C57BL/6J       20 min pretr.       0.01--05       s.c.           FC: impairment at higher dose (\>2 mg/kg)                                                      [@B161]
  **Antagonists**                                                                                                                                                                        
  BMY-7378            M: Swiss-W.       30 min pretr.       0--5           s.c.           PA: no effect                                                                                  [@B96]
  MC18                M: C57BL/6J       15 min pretr.       0.1--1         s.c.           PA: U-shaped PA retention facilitation (maximum at 0.3 mg/kg)                                  [@B119]
  NAD-299             M: C57BL/6J       20 min pretr.       0.3 and 1      s.c.           FC: increased freezing at 24-h test                                                            [@B161]
                      M: C57BL/6J       15 min pretr.       0.1--3         s.c.           PA: DD PA retention facilitation at 24-h test                                                  [@B91]
                      M: NMRI           15 min pretr.       0.1--3         s.c.           PA: U-shaped PA retention facilitation (maximum at 1 mg/kg)                                    [@B91]
  SRA-333             R: Sprague-D.     30 min pretr.       0.3--2         s.c.           PA: DD PA retention facilitation                                                               [@B138]
  (S)-UH-301          R: Sprague-D.     30 min pretr.       0--3           s.c.           PA: no effect                                                                                  [@B70]
  VP-08/34            M: C57BL/6J       15 min pretr.       0.3 and 1      s.c.           PA: no effect                                                                                  [@B119]
  WAY-100635          R: Sprague-D.     30 min pretr.       0.003--0.3     s.c.           PA: attenuated the PA retention deficit by PC A (0.03--0.1 mg/kg)                              [@B104]
                      R: Wistar         30 min pretr.       1              i.p.           PA: reversed MK-801-induced memory impairment                                                  [@B63]
                      R: Wistar         0 min post-tr.      0.01           i.v.           PA: reversed MK-801-induced memory impairment                                                  [@B63]
                      R: Sprague-D.     120 min pretr.      3              po.            FC: Reversed scopolamine-induced memory deficits                                               [@B59]

A, anxiety tests; DD, dose-dependent, FC, fear conditioning; i.h., intrahippocampal; i.p., intraperitoneal, i.v., intravenous; M, mice; n.a., not available; PA, passive avoidance; post-tr., post-training; p.o., per os; pretr, before training; R, rats; s.c., subcutaneous.

Systemic 5-HT~1A~ Receptor Ligand Effects
-----------------------------------------

Despite the differences among the 5-HT~1A~R ligands in their chemical and pharmacological features (e.g., receptor selectivity and partial or full agonist properties; see **Tables [1](#T1){ref-type="table"}** and **[2](#T2){ref-type="table"}**), there is strong evidence for the impairing effect of postsynaptic 5-HT~1A~R activation on fear memory. Systemic, pretraining administration of the full 5-HT~1A~R agonist 8-OH-DPAT shows a biphasic effect on PA performance, with the low dose range (0.01, 0.03 mg/kg) facilitating and the high dose range (0.1--1 mg/kg) impairing PA retention 24 h after training in both rats ([@B104]; [@B90]) and mice ([@B91]). The impairing dose of 8-OH-DPAT (0.2 and 0.3 mg/kg) also induces signs of the serotonin syndrome ([@B27]; [@B90]) linking the postsynaptic 5-HT~1A~R to the learning deficits. In line with these results, FC studies demonstrated that pretraining systemic injections of high doses (0.1--0.5 mg/kg) of 8-OH-DPAT impair fear learning ([@B143]; [@B161]). Pretreatment with the selective 5-HT~1A~R antagonist WAY-100635 (0.03--1 mg/kg) blocked the impairment in freezing (FC) and transfer latency (PA), confirming and extending the detrimental role of the postsynaptic 5-HT~1A~R activation on memory acquisition.

The observed memory deficit was already present in short-term memory tests performed 1 h after training for FC retention ([@B143]) and 5 min after PA training ([@B104]). Thus, postsynaptic 5-HT~1A~R activation specifically impairs memory encoding of the aversive experience and not memory consolidation. In agreement to that observation, immediate 8-OH-DPAT post-training administration did not alter PA or FC retention ([@B104]; [@B91]).

Local 5-HT~1A~ Receptor Ligand Effects
--------------------------------------

Intracranial administration of 5-HT~1A~R agonists and/or antagonists was used to further elucidate the distinct function of pre- versus postsynaptic 5-HT~1A~Rs in fear learning. Pre- but not post-training intra-hippocampal infusion of 8-OH-DPAT impairs contextual FC ([@B143]), pointing at the important role of the postsynaptic 5-HT~1A~R in acquisition processes as observed after systemic administration.

Effects of 5-HT~1A~ Receptor Agonists and Antagonists on Memory Recall
======================================================================

Systemic 5-HT~1A~ Receptor Ligand Effects
-----------------------------------------

Unlike the unambiguous implication of the postsynaptic 5-HT~1A~R in memory acquisition, its role in fear retrieval and expression is less clear. The systemic 5-HT~1A~R agonist NDO-008 (0.5 mg/kg) administered before the retention test to rats impairs slightly PA performance ([@B102]). In contrast, systemic administration of buspirone at the dose of 1 and 3 mg/kg had no effect on fear expression in mice ([@B121]). These different effects may partly depend on the readouts and the side effects elicited by higher 5-HT~1A~R dosages, such as the hypolocomotion induced together with the serotonin syndrome ([@B143]). The hypolocomotion confounds the interpretation of fear expression results in mice when based on freezing. Moreover, it also possible that differences exists between rats and mice, although our own data shows high similarity of results in these two species.

Therefore, a recent study tried to clarify the role of the 5-HT~1A~R in fear recall, by assessing the effect of 8-OH-DPAT on fear-conditioned HR responses (reviewed by [@B142]) upon training and 24 h after training, in mice ([@B160]). Systemic pretest administration reduced the conditioned maximum HR as a consequence of the significantly reduced baseline HR before the presentation of the conditioned stimulus (tone). However, the tone-induced HR increase was preserved during the retention of auditory fear in mice with similar magnitude as compared to that in controls. Additionally, 8-OH-DPAT reduced the unconditioned tachycardia elicited by novelty exposure as a consequence of altered HR dynamics indicating autonomic dysregulation with enhanced parasympathetic function through postsynaptic 5-HT~1A~R activation ([@B160]). Thus, the claims of anxiolytic actions of pretest injection of 5-HT~1A~R agonists as initially reported in human studies and partly in animal models cannot be supported unambiguously at least in learned fear experiments.

Local 5-HT~1A~ Receptor Ligand Effects
--------------------------------------

Local administration approaches tried to distinguish the role of the post- versus the presynaptic 5-HT~1A~R in the different aspects of fear expression. Bilateral microinjections of a selective 5-HT~1A~R agonist flesinoxan decreased the expression of conditioned contextual freezing when injected into the hippocampus or amygdala but not in the medial prefrontal cortex ([@B84]), as well as the fear-potentiated startle responses when infused into the central amygdala ([@B51]).

The role of 5-HT~1A~ autoreceptors in fear expression was also studied by pretest infusion of 8-OH-DPAT into the median raphe nuclei. This resulted in impaired contextual freezing responses ([@B21]; [@B3]), but not fear-potentiated startle ([@B51]; [@B3]) suggesting the existence of raphe-dependent serotonergic regulation that appears to modulate the freezing response to the aversive context. In contrast, hippocampal 8-OH-DPAT impaired the expression of both contextual freezing and fear-potentiated startle ([@B3]). However, 8-OH-DPAT mediates hyperlocomotion in rats (but hypolocomotion in mice) leading to a similar problem of potentially confounded interpretation of freezing performance during the drug state as mentioned before for mice.

Effects of 5-HT~1A~ Receptor Agonists and Antagonists on Memory Extinction
==========================================================================

In contrast to the well-studied implication of 5-HT~1A~Rs on memory acquisition and recall, there is only one study with 5-HT~1A~R ligands on fear extinction. The systemic 5-HT~1A~R agonist buspirone abolishes the fear extinction in mice ([@B121]). Similarly, the systemic 5-HT~1A~R antagonist WAY-100635 before a second sampling trial impaired the extinction of object recognition memory in rats ([@B118]). Further studies are needed to determine the precise role of 5-HT~1A~Rs in memory extinction and/or reconsolidation in emotional learning tasks. Furthermore, local rather than systemic approaches are necessary to identify the neurocircuitry involved in these processes. The roles of other 5-HTRs in fear learning and the consequences of altered 5-HT neurotransmission on fear extinction are reviewed by [@B62].

Effects of 5-HT~7~ Receptor Agonists and Antagonists on Emotional Learning
==========================================================================

Systemic 5-HT~7~ Receptor Ligand Effects
----------------------------------------

The paucity of studies 5-HT~7~R functions on emotional learning is mainly due to the lack of selective ligands, especially agonists ([@B104]; [@B81]; [@B82]; see **Table [5](#T5){ref-type="table"}** and text above). Recent data from an autoshaping task showing that the 5-HT~7~R agonist, LP-211, when administered systematically after the training session, reversed scolopamine-induced amnesia, in rats ([@B98]). The same group also shows a facilitating effect on memory formation by the 5-HT~7~R agonist AS-19 administered after an autoshaping training session ([@B116]). The enhancing effect of 5-HT~7~Rs on memory consolidation was blocked by pre-injection of the 5-HT~7~R antagonist SB-269970 ([@B116]; [@B98]) indicating the specific involvement of the 5-HT~7~R.

###### 

Overview of the behavioral effects of 5-HT~7~ receptor agonists and antagonists in learning tasks (not restricted to fear learning).

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Compound              Species: Strain   Time of injection   Dose (mg/kg)   Admin. route   Behavior assay and behavioral consequences                                                              References
  --------------------- ----------------- ------------------- -------------- -------------- ------------------------------------------------------------------------------------------------------- ------------
  **Agonists**                                                                                                                                                                                      

  AS-19                 M: C57BL/6J       15 min pretr.       3--10          i.p.           DD activity reduction\                                                                                  [@B40]
                                                                                            PA: no effect in retention latencies, 24 h after training                                               

                        R: Wistar         0 min post-tr.      0.5--10.0      s.c            P/I-A: Enhanced memory consolidation, 24 h after training                                               [@B116]

  LP-211                R: Wistar         0 min post-tr.      0.1--10.0      i.p.           P/I-A: only 0.5 mg/kg had a possitive effect on memory consolidation, when tested 24 h after training   [@B98]

  LP-44                 M: C57BL/6J       15 min pretr.       1--10          i.p.           PA: DD activity reduction but no effect on PA retention latencies tested 24 h after training            [@B40]

  NAD-299 + 8-OH-DPAT   M: C57BL/6J       30 min\             0.3 + 1        s.c.           PA: facilitates retention latencies 24 h after training serving as 5-HT~7~R activation                  [@B40]
                                          +15 min pretr.                                                                                                                                            

  **Antagonists**                                                                                                                                                                                   

  DR4004                R: Wistar         0 min post-tr.      0.5--10.       i.p.           P/I-A: no effect                                                                                        [@B97]

  SB-269970             R: Wistar         0 min post-tr.      1--20          i.p.           P/I-A: no effect                                                                                        [@B97]

                        M: C57BL/6J       30 min pretr.       20             s.c.           PA: reversed the facilitation by 8-OH-DPAT + NAD-299                                                    [@B40]

  SB-656104-A           R: Wistar         60 min pretr.       10 and 30      i.p.           PA: reversed MK-801-induced memory impairment                                                           [@B63]

                        R: Wistar         60 min pretr.       0.3            i.p.           PA: Counteracted the effect of MK-801                                                                   [@B63]

                                                                                                                                                                                                    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A, anxiety tests; DD, dose dependent, FC, fear conditioning; i.h., intrahippocampal; i.p., intraperitoneal, i.v., intravenous; M, mice, MSRAP, multiple schedule repeated acquisition performance; MWM, Morris water maze; n.a., not available; OR, object recognition task; OT, operant task; PA, passive avoidance; P/I-A, Pavlovian/instrumental autoshaping task; post-tr., post-training; p.o., per os; pretr, before training; R, rats; s.c., subcutaneous.

[@B41] investigated the role of 5-HT~7~R on emotional learning in mice using a step-through PA paradigm. Pretraining systemic administration of the 5-HT~7~R antagonist SB-269970 enhanced the impairing effect of low doses of 8-OH-DPAT ([@B41]). This result supports the notion that 5-HT~7~R activation has a beneficial modulatory role in learning opposing the function of 5-HT~1A~R activation. Accordingly, pretraining 5-HT~7~R activation by the combined use of the 5-HT~1A~R antagonist NAD-299 with the 5-HT~1A~R and 5-HT~7~R agonist 8-OH-DPAT facilitated PA retention ([@B40]). This PA facilitation by NAD-299 together with 8-OH-DPAT was again blocked by the 5-HT~7~R antagonist SB-269970 indicating a procognitive effect of 5-HT~7~R activation by this drug combination. However, the 5-HT~7~R agonists LP-44 and AS-19 failed to mediate this PA facilitation, despite dose-dependent tests. Despite their high *in vitro* potency to stimulate intracellular signaling cascades ([@B40]), the 5-HT~7~R agonists LP-44 and AS-19 have moderate agonist efficacy *in vivo*. This finding is in agreement with previous pharmacological characterization ([@B106]; [@B22]; [@B24]) *in vivo* and may explain why the facilitatory effect of NAD-299 with 8-OH-DPAT could not be mimicked by the putative agonists LP-44 and AS-19.

Local 5-HT~7~ Receptor Ligand Effects
-------------------------------------

To further address the role of 5-HT~7~Rs on emotional learning, [@B40] performed hippocampal infusions with the 5-HT~7~R agonist AS-19 in mice. Since they failed to find clear facilitatory effects, as observed after systemic treatment, they concluded that "5-HT~7~Rs appear to facilitate memory processes in a broader cortico-limbic network and not the hippocampus alone." The failure of the SB-269970 to enhance emotional memory, upon hippocampal infusions, may be the consequence of the low dose that can be locally infused due to the relatively poor solubility of SB-269970. However, systemic administration of this 5-HT~7~R antagonist fully blocked the PA facilitation observed after 5-HT~1A~R blockade. Hence, the hippocampus-dependent involvement of the 5-HT~7~Rs needs to be re-investigated with selective highly potent 5-HT~7~R agonists, because also the low potency of AS-19 ([@B40]) may have contributed to the lack of effects by dorsohippocampal 5-HT~7~R agonist application on PA. Finally, although the role of 5-HT~7~R in memory consolidation has been suggested, there are currently insufficient data supporting this view. More work is also required to clarify the role of 5-HT~7~R in memory extinction and reconsolidation, which are both essentially unexplored.

The Interplay of the 5-HT~1A~ and 5-HT~7~ for Emotional Learning
================================================================

The interaction of the two 5-HTR subtypes in emotional learning has been studied by using 8-OH-DPAT, which exerts agonistic effects for both 5-HT~1A~Rs and 5-HT~7~Rs. To dissect the function of these 5-HTRs, pre-treatment with selective 5-HT~1A~R antagonists is used to exclusively activate 5-HT~7~R. [@B41] were the first to suggest the functional interplay between the two 5-HTRs on the behavioral level as the activation of 5-HT~7~R counteracted the 5-HT~1A~R-mediated impairments in PA performance. The interaction between the two 5-HTRs and their functional antagonism was then extended by experiments in mice, demonstrating that 5-HT~7~R activation and concomitant 5-HT~1A~R blockade leads to PA facilitation ([@B40]). The facilitatory effect on emotional memory by the 5-HT~1A~ antagonist NAD-299 was related to stimulation of 5-HT~7~Rs under conditions with reduced 5-HT~1A~R transmission. These findings suggest that the states of 5-HT~1A~Rs and 5-HT~7~Rs play a critical role for 5-HT effects on emotional memory. Consequently, the elevation of endogenous 5-HT via SSRIs will most likely result in differential cognitive/emotional effects depending on genetic and/or epigenetic regulation and occupancy of these two 5-HTRs in health and disease. This condition will affect the expression of the 5-HT~1A~R and change the relative balance between 5-HTR subtypes, which together will eventually determine the physiological actions of 5-HT and the clinical efficacy of SSRI treatment.

Mechanisms Underlying the Functional Interaction of 5-HT~1A~R and 5-HT~7~R
==========================================================================

As described above, 5-HT~1A~Rs and 5-HT~7~Rs mediate opposing effects regarding the neuronal excitability. 5-HT~1A~R activation reduces the activity of adenyl cyclase, whereas 5-HT~7~R activation stimulates adenyl cyclase activity and thereby increases intracellular cAMP thereby increasing neuronal excitability ([@B19]; [@B110]; [@B16]). Accordingly, 5-HT~7~R stimulation in the hippocampus was found to activate pyramidal neurons, unlike 5-HT~1A~R activation which inhibited pyramidal neurons ([@B17]). Both 5-HTRs are expressed in glutamatergic hippocampal pyramidal neurons ([@B19]; [@B110]; [@B16]). Therefore, it is likely that 5-HT~1A~R and 5-HT~7~R stimulation decreases and increases glutamate release in the hippocampus, respectively. In line with these results, 5-HT~7~R activation enhances the AMPA receptor-mediated synaptic currents on CA1 pyramidal neurons, whereas 5-HT~1A~R activation inhibits the AMPA receptor-mediated transmission between CA3 and CA1 pyramidal neurons in both pre- and postsynaptic sites ([@B32]). However, the 5-HT~1A~R-mediated inhibitory effect on glutamatergic neurotransmission was stronger than the 5-HT~7~R-mediated facilitatory effect ([@B32]). One explanation for the increased effectiveness of 5-HT~1A~R in controlling the input from the Schaffer collaterals may stem from the different localization of the two receptors on the CA1 pyramidal neurons: 5-HT~7~Rs are found on the cell bodies ([@B17]), whereas the 5-HT~1A~Rs appear to be mainly localized on dendrites ([@B74]).

Differences in the expression of the receptors could also play an essential role in their distinct activation pattern from the endogenous 5-HT. The progressive reduction of post-synaptic 5-HT~7~R levels during postnatal development, together with the maintenance of the expression level of 5-HT~1A~R ([@B76]; [@B126]), could increase the ratio of membrane 5-HT~1A~Rs over 5-HT~7~Rs. Consequently, a model has been proposed regarding the molecular mechanisms that underlie the regulation of the 5-HT~1A~Rs and 5-HT~7~Rs. 5-HT~1A~R and 5-HT~7~R form heterodimers both *in vitro* and *in vivo* ([@B126]). This heterodimerization plays a functional role by decreasing G~i~ protein coupling of the 5-HT~1A~R and by reducing the ability of 5-HT~1A~R to activate potassium channels, without affecting the G~s~ protein coupling of the 5-HT~7~R. The heterodimerization additionally contributes to the desensitization of the 5-HT~1A~R through facilitated internalization ([@B126]).

5-HT~1A~R and 5-HT~7~R are co-localized in the cell membrane of hippocampal neurons, where their heterodimerization induces an inhibitory effect on the 5-HT~1A~R-mediated activation of potassium channels in hippocampal neurons ([@B126]). As mentioned above the post-synaptic levels of 5-HT~7~R are lower compared to the expression levels of post-synaptic 5-HT~1A~R, whereas this is not the case for the pre-synaptic 5-HT~7~R ([@B126]). These regional differences in the 5-HT~7~R levels and therefore in the concentration of the heterodimers, can explain the preferential desensitization of 5-HT~1A~ autoreceptors by SSRIs and more generally the region- and cell- specific differences in the signaling pathway mediated by the 5-HT~1A~R activation (see [@B108]). In summary, the above data suggest that the positive or negative consequences of a drug on emotional memory and cognition depend on the relative level of 5-HTR expression and, its efficacy in activating different receptors with their downstream signaling pathways.

Genetic and Epigenetic Effects on 5-HT Transmission and Receptor Expression
===========================================================================

Genetic and/or epigenetic effects regulate the receptor's state and eventually define the physiological actions of endogenous 5-HT. A characteristic example is the Ala50Val variant of the 5-HT~1A~R, located in the transmembrane region 1, that leads to loss of response to 5-HT and consequently to the interruption of 5-HT signaling ([@B36]). Moreover, the human polymorphism Gly22Ser attenuates the downregulating effect induced by long-term 8-OH-DPAT stimulation in comparison to the Val28 variant and wild-type without effect on the ligand binding capacity ([@B129]). It is suggested that individuals with the Ser22 variant have higher sensitivity to SSRIs treatment since its serotonergic effect depends on the efficiency of 5-HT~1A~R transmission ([@B129]). Furthermore, carriers of the short (s) allele of the 5-HT transporter promotor region possess behavioral abnormalities, such as increased levels of anxiety and FC as well as stronger fear potentiated startle ([@B11]) in comparison to long (l) allele carriers. Accordingly, the therapeutic efficacy of SSRIs is reduced in patients homozygous for the s-allele when compared with heterozygous or l-allele carriers ([@B151]).

The epigenetic regulation of 5-HTR subtypes is also implicated in the differential emotional and cognitive modulation induced by the serotonergic signaling. It is widely accepted that 5-HT~1A~R binding is reduced in the brain of depressed humans (e.g., [@B133]) as well as in stressed rats (e.g., [@B30]) as indication of epigenetic modulation. 5-HT~1A~R activation in the basolateral amygdala and the prelimbic area of the prefrontal cortex in low-anxious rats reduced fear potentiated startle, whereas 5-HT~1A~R activation in the periaqueductal gray of high-anxious rats had the opposite effect ([@B43]). These findings highlight how environmental conditions can contribute to individual differences in 5-HT~1A~R-mediated response differences. In line with this, single-housed mice display a stronger hypothermic effect upon 5-HT~1A~R activation by 8-OH-DPAT, which is associated with an increased depressive-like state, in comparison to their group-housed counterparts ([@B72]). However, the mechanisms underlying the inter-individual differences in serotonergic signaling and consequently in cognitive and emotional modulation are not clear yet.

A linkage disequilibrium study identified two polymorphisms (rs3808932 and rs12412496) in the human *HTR7* suggesting that it is a schizophrenia susceptibility gene ([@B68]). However, to the best of our knowledge, there is no evidence for the effect of 5-HT~7~R polymorphisms on serotonergic signaling or the interaction between polymorphisms of 5-HT~7~ and 5-HT~1A~Rs. Therefore, to elucidate the functional interaction between 5HT~1A~R and 5-HT~7~R, it is of high importance to understand which polymorphisms influence the expression of those 5-HTRs and how these changes affect emotional and cognitive functions. This knowledge could potentially reveal the polymorphisms that modulate the endophenotypes of different affective disorders, closely linked with the function of 5-HT~1A~R and 5-HT~7~R, such as anxiety and depression.

Neurochemical Effects in the Hippocampus
========================================

In contrast to the above electrophysiological results, *in vivo* microdialysis in awake rats showed that the local blockade of 5-HT~1A~R increased extracellular acetylcholine (ACh) levels ([@B91]; [@B59]; [@B73]) but failed to show changes in hippocampal glutamate release in the ventral hippocampus and the prefrontal cortex ([@B73]). The result with ACh is consistent with the pro-cognitive effect of (postsynaptic) 5-HT~1A~R blockade in PA ([@B91]). However, the expected glutamate increase may not be detectable because of the limited capacity of microdialysis to detect small transmitter changes restricted to the synaptic cleft. More sensitive techniques are required such as enzyme-based microelectrode amperometry, which is selective for the detection of extracellular glutamate with (1) spatial resolution in the μm level, (2) sub-second temporal resolution and (3) sensitivity in the μm range of glutamate ([@B33]; [@B77]; [@B105]). This novel technology is suited to provide evidence for the expected enhancement of glutamatergic transmission in the hippocampus by both 5-HT~1A~R inhibition and 5-HT~7~R activation.

It is clear that the impairing effects of low dose NMDA receptor antagonists (e.g., MK-801) and cholinergic antagonist (e.g., scopolamine) can be prevented by serotonergic manipulations ([@B112]). Thus, these two pharmacological models of cognitive impairment relevant for Alzheimer's disease are both alleviated by 5-HT~1A~R inhibition demonstrating a role for both enhanced glutamatergic and cholinergic transmission for improved cognitive function (e.g., [@B134]; [@B91]). An overview of these modulatory effects is provided in **Figure [1](#F1){ref-type="fig"}**.

![**Simplified overview of 5-HT~1A~R- and 5-HT~7~R-mediated modulation of fear learning in pre- and postsynaptic neurons under conditions of high (A) and low presynaptic 5-HT~1A~R activation (B), resulting in low and high postsynaptic 5-HT release, respectively.** This in turn causes increased and decreased acetylcholine (ACh) release in the hippocampus (and also the medial septum). A similar effect on hippocampal glutamate (Glu) levels is hypothesized (as shown in the medial septum). When high postsynaptic 5-HT levels are biased to 5-HT~7~R activation **(C)**, e.g., by 8-OH-DPAT at the postsynaptic dose of 1 mg/kg in combination with the 5-HT~1A~R antagonist NAD-299 at 0.3 mg/kg, a pro-cognitive effect in fear learning is observed. Thus, emotional learning and memory depend on intrasynaptic 5-HT levels, receptor availability and occupancy, genetic and epigenetic factors for 5-HTR regulation and its short- and long-term mechanisms underlying altered synaptic transmission via ACh and glutamate (Glu) release. Under conditions of higher (postsynaptic) 5-HT release, the cognitive consequences depend on the availability and occupancy of 5-HT~1A~R and 5-HT~7~Rs with so far unknown conditions that bias toward impaired **(B)** or facilitated fear memory **(C)**. The specific functions of GABAergic interneurons in 5-HT~1A~R and 5-HT~7~R-mediated fear memory modulation are currently not understood.](fphar-06-00162-g001){#F1}

Conclusion and Future Perspectives
==================================

During the last three decades many studies have indicated important regulatory functions of 5-HT signaling for emotional and cognitive functions. However, the complexity of the serotonergic signaling due to the existence of at least 14 pre- and postsynaptic 5-HTRs subtypes with multiple transduction mechanisms makes it exceedingly difficult to assign unambiguously the physiological and behavioral role of a single 5-HTR subtype. However, the use of specific ligands in combination with systemic and intrahippocampal administration, receptor autoradiography and *in vivo* neurochemical measurements are powerful tools in identifying the action of specific ligands in local networks of the brain including subareas of the hippocampus. This approach, combined with *in vivo* electrophysiology and genetic tools, can also better define the functional role of 5-HT in the neuronal circuitry underlying cognitive function.

Overall a number of open questions need to be answered to further improve our understanding of the role of serotonergic signaling via the different 5-HTRs in health and disease:

1.  How do 5-HTRs modulate hippocampal and cortical glutamatergic transmission with a focus on activation and inhibition of 5-HT~1A~Rs and 5-HT~7~Rs? This needs to be determined with newly developed amperometry methods in *in vivo* recordings.

2.  What are the roles of 5-HT~1A~Rs and 5-HT~7~Rs in defined hippocampal subregions for emotional and cognitive functions? This requires the development of new ligands with low lipophilicity for local actions tested *in vivo*. Alternatively, is should be possible to shut down the second messenger coupling of neurons selectively expressing 5-HT~1A~Rs and 5-HT~7~Rs by Designer Receptors Exclusively Activated by Designer Drugs (DREADD) technology.

3.  What are the roles of 5-HT~1A~Rs and 5-HT~7~Rs in different memory phases? As indicated there are considerable inconsistencies about the role of 5-HT~1A~Rs and 5-HT~7~Rs in the consolidation process. In addition, extinction and reconsolidation are so far poorly explored.

4.  The regulation of 5-HTR expression has so far focused on the 5-HT~1A~R. This needs to be extended to other 5-HTRs including the 5-HT~7~R. Besides the use of radio-ligands in imaging studies, the subcellular immunohistochemical analyses of 5-HTR protein levels requires the development of specific antibodies.

5.  Finally, despite the evidence of the beneficial effects of 5-HT~1A~R antagonists in preclinical models, the therapeutic potential to facilitate cholingergic and/or glutamatergic neurotransmission for improved cognitive function in human neuropathology (e.g., Alzheimer's disease) or in aging is so far not explored.
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5-HT

:   5-hydroxytryptamine

5-HTR

:   5-HT receptor

cAMP

:   cyclic AMP

CNS

:   central nervous system

Epac

:   exchange proteins directly activated by cAMP

ERK

:   extracellular signal-related kinase

FC

:   fear conditioning

HR

:   heart rate

MAPK

:   mitogen-activated protein kinase

PA

:   passive avoidance

PKA

:   protein kinase A

SSRI

:   selective serotonin reuptake inhibitor
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